Perioperative corticosteroid treatment impairs tumor-infiltrating dendritic cells in patients with newly diagnosed adult-type diffuse gliomas

Front Immunol. 2023 Jan 10:13:1074762. doi: 10.3389/fimmu.2022.1074762. eCollection 2022.

Abstract

Introduction: Adult-type diffuse gliomas are malignant primary brain tumors characterized by very poor prognosis. Dendritic cells (DCs) are key in priming antitumor effector functions in cancer, but their role in gliomas remains poorly understood.

Methods: In this study, we characterized tumor-infiltrating DCs (TIDCs) in adult patients with newly diagnosed diffuse gliomas by using multi-parametric flow cytometry and single-cell RNA sequencing.

Results: We demonstrated that different subsets of DCs are present in the glioma microenvironment, whereas they are absent in cancer-free brain parenchyma. The largest cluster of TIDCs was characterized by a transcriptomic profile suggestive of severe functional impairment. Patients undergoing perioperative corticosteroid treatment showed a significant reduction of conventional DC1s, the DC subset with key functions in antitumor immunity. They also showed phenotypic and transcriptional evidence of a more severe functional impairment of TIDCs.

Discussion: Overall, the results of this study indicate that functionally impaired DCs are recruited in the glioma microenvironment. They are severely affected by dexamethasone administration, suggesting that the detrimental effects of corticosteroids on DCs may represent one of the mechanisms contributing to the already reported negative prognostic impact of steroids on glioma patient survival.

Keywords: brain tumors; dendritic cells; immune suppressive tumor microenvironment; perioperative corticosteroids; single cell-RNA sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / pathology
  • Dendritic Cells
  • Glioma*
  • Humans
  • Prognosis
  • Tumor Microenvironment

Substances

  • Adrenal Cortex Hormones

Grants and funding

This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 14687) and Humanitas Research Hospital (Intramural Research and Clinical Funding Programs 5x1000 2018) grants to DM; AIRC (IG-19213) and Ministero della Salute (RF-2019-12371549) to ML; Department of Medical Biotechnologies and Translational Medicine, University of Milan (2019 and 2020 Intramural Programs) grants to SDB; AIRC (IG 20269) and Ministero dell’Università e della Ricerca (PRIN 20177J4E75) grants to RB; CC and SF were supported by the Doctorate School of Experimental Medicine and Medical Biotechnologies, University of Milan; FC was supported by Fondazione Umberto Veronesi (2020-3274); CC was supported by AIRC (fellowship lotteria vincere insieme per la ricerca 25491); ST was supported by the Data Science in Medicine and Nutrition (DASMEN) Ph.D. program from Humanitas University; JM was supported by type A 2017-PDF-0149 fellowship from the University of Milan.